Another important phase I clinical trial in sarcoma is aimed at testing the combination of anti-HER2 CAR T-cell therapy in combination with immune checkpoint blocking agents such as pembrolizumab or nivolumab (NCT04995003). Here, ERBB2 is linked to sarcoma.